1 / 12 2 / 12 3 / 12 4 / 12 5 / 12 6 / 12 7 / 12 8 / 12 9 / 12 10 / 12 11 / 12 12 / 12 ❮ ❯ Imfinzi ® (durvalumab) is the first and only approved immunotherapy for people with unresectable stage 3 nsclc whose disease has not progressed following concurrent.